About
NuvOx Therapeutics, Inc.
NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role. Our product candidate is NanO2, the API of which is dodecafluoropentane.
NanO2 is administered intravenously as an emulsified liquid, containing nano-sized droplets that after entering the body, due to the human body temperature, convert to a gas, which enables them to deliver more oxygen than when in the liquid state.
The focus of our clinical research and development to date has been on the administration of NanO2 to treat acute ischemic stroke, GBM, ARDS, and sickle cell anemia.
NuvOx Therapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Valuation & Multiples
Key valuation ratios and metrics
Financial Highlights
Historical financial performance
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Jul 17, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | May 6, 2025 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Apr 8, 2025 | [Amend] [Cover] Draft Registration Statement |
| DRS | Dec 23, 2024 | [Cover] Draft Registration Statement |
| D | Nov 22, 2024 | Notice of Exempt Offering of Securities |
| D | Feb 15, 2023 | Notice of Exempt Offering of Securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Evan Unger, M.D.
Executive Chairman of the Board
Rong Wang
President, Chief Executive Officer and Director
Shien McCullough, CPA
Interim Chief Financial Officer
Jennifer L. H. Johnson, Ph.D.
Chief Operating Officer
Richard Carmona, M.D.
Director
Jon S. Saxe
Director
Jonathan T. Schilling
Director
Marvin J. Slepian, M.D
Director
Wilson W. Cheung, CPA
Director
